

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1-14. (Cancelled).

15. (Previously presented) A triterpene saponin prepared by a process for the isolation of triterpene saponins belonging to the family *Myrsinaceae*, wherein said saponin is isolated from the plant species *Maesa balansae*, said process comprising

- (a) extracting dried plant parts with an alcohol and concentrating the extract,
- (b) removing the apolar fraction from the extract by liquid-liquid extraction with an apolar solvent, and
- (c) further purifying the saponin in the alcohol extract by liquid -liquid extraction, filtration and chromatography, wherein the chromatography comprises reversed-phase liquid chromatography with gradient eluent system using

A : 0.5 % ammonium acetate in water

B : methanol

C : acetonitrile

wherein at $t = 0$, (A:B:C) = (60:20:20) and at $t = \text{end}$, (A:B:C) = (0:50:50), and wherein said saponin has the following characteristics:

Compound 1 : MW = 1532, λ_{max} = 228.6 nm, $\lambda_{\text{max}2}$ = 273.3 nm ;

Compound 2 : MW = 1510, λ_{max} = 223.9 nm, $\lambda_{\text{max}2}$ = 274.5 nm ;

Compound 3 : MW = 1532, λ_{max} = 279.2 nm, $\lambda_{\text{max}2}$ = 223.9 nm ;

Compound 4 : MW = 1510, λ_{max} = 280.4 nm, $\lambda_{\text{max}2}$ = 222.7 nm ;

Compound 5 : MW = 1574, λ_{max} = 276.8 nm, $\lambda_{\text{max}2}$ = 225.0 nm ; or

Compound 6 : MW = 1552, λ_{max} = 279.2 nm, $\lambda_{\text{max}2}$ = 223.9 nm.


16. (Previously presented) The triterpene saponin according to claim 15 wherein the alcohol is methanol, ethanol, isopropanol, or butanol, each optionally admixed with water.

17. (Currently amended) A process according to claim 15 wherein the saponins of the alcohol extract are further purified by

(e6) extracting the aqueous fraction with butanol saturated with water,
(e7) evaporating the organic layer to dryness,
(e8) washing the residue in a ketone, and
(e9) filtering off the crude saponin mixture.

18. (Previously presented) A pharmaceutical composition comprising a pharmaceutically acceptable excipient and as an active ingredient a triterpene saponin according to claim 15.

19. (Previously presented) A method of alleviating clinical manifestations of, and treating disorders known as leishmaniasis attributable to infection by protozoan parasites of the genus *Leishmania* in both humans and animals, comprising administering to an infected host a therapeutically effective amount of a compound of formula:



a stereoisomeric form thereof or a pharmaceutically acceptable addition salt thereof, wherein
R₁ is hydrogen, -(C=O)C₁₋₅alkyl, -(C=O)C₂₋₅alkenyl, -(C=O)C₂₋₅alkenyl substituted with phenyl, a monosaccharide group or an oligosaccharide group ;
R₂ is hydrogen, hydroxy, -O(C=O)C₁₋₅alkyl, -O(C=O)C₂₋₅alkenyl, -O(C=O)C₆H₅, or -O(C=O)C₂₋₅alkenyl substituted with phenyl ;
R₃ is hydrogen, hydroxy, -O(C=O)C₁₋₅alkyl, -O(C=O)C₂₋₅alkenyl, -O(C=O)C₆H₅, or -O(C=O)C₂₋₅alkenyl substituted with phenyl ;
R₄ is hydrogen, C₁₋₆alkyl, -(C=O)C₁₋₅alkyl, -(C=O)C₂₋₅alkenyl, -(C=O)C₆H₅, or -(C=O)C₂₋₅alkenyl substituted with phenyl ;
R₅ is CH₃, CH₂OH, CH₂OCH₃, CH₂O-C(=O)CH₃, CHO, or COOH ; or

R₅ and R₂ form a divalent radical of formula -C(=O)-O- ;

R₆ and R₇ are hydrogen; or taken together they form a bond; or R₅ and R₆ form a divalent radical of formula

-CH₂-O- (a),

-CH(OR₁₃)-O- (b), or

-C(=O)-O- (c),

wherein R₁₃ is hydrogen, C₁₋₆alkyl or -(C=O)C₁₋₅alkyl ;

R_{8α} and R_{8β} each independently represent CH₃, CH₂OH, CH₂OCH₃, CH₂O-C(=O) C₁₋₅alkyl, CHO, CH(OCH₃)₂, CH=NOH, or COOH ; or R_{8β} and R₃ form a divalent radical of

formula -C(=O)-O- ; or R_{8β} and R₅ form a divalent radical of formula -CH₂O-CHOH- ;

R₉ is CH₃, CH₂OH, CH₂OCH₃, CH₂O-C(=O)C₁₋₅alkyl, CHO, or COOH ;

R₁₀ is CH₃, CH₂OH, CH₂OCH₃, CH₂O-C(=O)C₁₋₅alkyl, CHO, or COOH ;

R₁₁ is hydrogen, hydroxy or O-C(=O)C₁₋₅alkyl ; or R₁₀ and R₁₁ form a divalent radical of formula -CH₂O- ; and

R₁₂ is CH₃, CH₂OH, CH₂OCH₃, CH₂O-C(=O)CH₃, CHO, CH=NOH, or COOH.

20. (Previously presented) The method according to claim 19 wherein

R₁ is hydrogen, -(C=O)C₁₋₅alkyl, or an oligosaccharide group ;

R₃ is hydrogen, hydroxy, -O(C=O)C₁₋₅alkyl, -O(C=O)C₂₋₅alkenyl, or -O(C=O)C₂₋₅alkenyl substituted with phenyl ;

R₄ is hydrogen, C₁₋₆alkyl, -(C=O)C₁₋₅alkyl, or -(C=O)C₂₋₅alkenyl ;

R₅ is CH₂OH, CH₂O-C(=O)CH₃, or CHO ; and

R₆ and R₇ taken together form a bond; or

R₅ and R₆ form a divalent radical of formula

-CH₂-O- (a),

-CH(OR₁₃)-O- (b), or

-C(=O)-O- (c),

wherein R₁₃ is hydrogen, C₁₋₆alkyl or -(C=O)C₁₋₅alkyl, ; and

R₇ is hydrogen ;

R_{8β} represents CH₃, CH₂OH, CHO, CH(OCH₃)₂, CH=NOH, or COOH ;

R_{8α} represents CH₃ ;

R_{8β} and R₃ form a divalent radical of formula -C(=O)-O- ; or

R_{8β} and R₅ form a divalent radical of formula -CH₂O-CHOH- ;

R₁₀ is CH₃, CH₂OH ;

R₁₁ is hydrogen, hydroxy or O-C(=O)C₁₋₅alkyl ; or

R₁₀ and R₁₁ form a divalent radical of formula -CH₂O- ; and

R₁₂ is CH₃, CH₂OH, CH₂O-C(=O)CH₃, CHO, or CH=NOH.

21. (Previously presented) The method according to claim 20 wherein

R₁ is hydrogen or an oligosaccharide group ;

R₂ is hydrogen, hydroxy, -O(C=O)C₁₋₅alkyl, -O(C=O)C₂₋₅alkenyl, -O(C=O)C₆H₅, or -O(C=O)C₂₋₅alkenyl substituted with phenyl ;

R₃ is hydrogen, hydroxy, -O(C=O)C₁₋₅alkyl, -O(C=O)C₂₋₅alkenyl, or -O(C=O)C₂₋₅alkenyl substituted with phenyl ;

R₄ is hydrogen, C₁₋₆alkyl, -(C=O)C₁₋₅alkyl, -(C=O)C₂₋₅alkenyl, or -(C=O)C₂₋₅alkenyl substituted with phenyl ;

R₅ is CH₂OH, CH₂OCH₃, CH₂O-C(=O)CH₃, CHO, or COOH ; and

R₆ and R₇ taken together form a bond; or

R₅ and R₆ form a divalent radical of formula

-CH₂-O- (a),

-CH(OR₁₃)-O- (b), or

-C(=O)-O- (c),

wherein R₁₃ is hydrogen ; and

R₇ is hydrogen ;

R_{8α} and R_{8β} both represent CH₃ ;

R₉ is CH₃ ;

R₁₀ is CH₃ ;

R₁₁ is hydrogen ; and

R₁₂ is CH₃.